[
  {
    "ts": "2026-01-14T19:05:56+00:00",
    "headline": "JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries",
    "summary": "The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.",
    "url": "https://www.pharmaceutical-technology.com/news/jpm26-regeneron-will-not-overpay-in-ma-deals-amid-lead-asset-patent-expiries/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "375e4db9-6181-3821-9bcb-4290020235b0",
      "content": {
        "id": "375e4db9-6181-3821-9bcb-4290020235b0",
        "contentType": "STORY",
        "title": "JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries",
        "description": "",
        "summary": "The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.",
        "pubDate": "2026-01-14T19:05:56Z",
        "displayTime": "2026-01-14T19:05:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/dcf209ea892e803958fbc3cccb3050d7",
          "originalWidth": 883,
          "originalHeight": 589,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VFlbyMvvq8ElHARcb9DQJg--~B/aD01ODk7dz04ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/dcf209ea892e803958fbc3cccb3050d7.cf.webp",
              "width": 883,
              "height": 589,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FIToxu2r2zojgF8v6k3sZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/dcf209ea892e803958fbc3cccb3050d7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/jpm26-regeneron-will-not-overpay-in-ma-deals-amid-lead-asset-patent-expiries/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-regeneron-not-overpay-m-190556340.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T21:10:00+00:00",
    "headline": "Is Regeneron (REGN) Offering Value After Recent Share Price Swings?",
    "summary": "If you are wondering whether Regeneron Pharmaceuticals at around US$758.91 represents fair value or a potential opportunity right now, you are not alone. The stock has had mixed recent returns, with a 2.3% decline over the last 7 days, a 2.4% gain over the last 30 days, a 2.2% decline year to date, and a 10.5% return over the past year, alongside 4.8% and 42.9% returns over the last 3 and 5 years. Recent attention on Regeneron has centered on its position in the pharmaceuticals and biotech...",
    "url": "https://finance.yahoo.com/news/regeneron-regn-offering-value-recent-211000184.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2255b622-a260-300b-8ca0-d3d6ddf8c62e",
      "content": {
        "id": "2255b622-a260-300b-8ca0-d3d6ddf8c62e",
        "contentType": "STORY",
        "title": "Is Regeneron (REGN) Offering Value After Recent Share Price Swings?",
        "description": "",
        "summary": "If you are wondering whether Regeneron Pharmaceuticals at around US$758.91 represents fair value or a potential opportunity right now, you are not alone. The stock has had mixed recent returns, with a 2.3% decline over the last 7 days, a 2.4% gain over the last 30 days, a 2.2% decline year to date, and a 10.5% return over the past year, alongside 4.8% and 42.9% returns over the last 3 and 5 years. Recent attention on Regeneron has centered on its position in the pharmaceuticals and biotech...",
        "pubDate": "2026-01-14T21:10:00Z",
        "displayTime": "2026-01-14T21:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-regn-offering-value-recent-211000184.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-regn-offering-value-recent-211000184.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]